SAN FRANCISCO -- Inhaled corticosteroid and long-acting beta2 agonist therapy significantly slows the progressive lung function decline of chronic obstructive pulmonary disease (COPD).

SAN FRANCISCO, May 22 -- Inhaled corticosteroid and long-acting beta₂ agonist therapy significantly slows the progressive lung function decline of chronic obstructive pulmonary disease (COPD).

Fluticasone proprionate plus salmeterol (Advair) reduced the decline in forced expiratory volume (FEV₁) by 16 mL per year compared with placebo (P

Enhance your clinical practice with the Patient Care newsletter, offering the latest evidence-based guidelines, diagnostic insights, and treatment strategies for primary care physicians.

Subscribe Now!

ATS: COPD Drugs Slow Disease Progression, Study Confirms

Newsletter